


CDMO Live Debuts as BioPharma Manufacturing Sector Approaches \$200 Billion

26 February 2025 | News

A new event dedicated to biopharmaceutical contract manufacturing launches this May as the sector approaches a historic \$200 billion milestone.



<u>CDMO Live</u> has emerged as the definitive industry gathering, bringing together Europe's leading pharmaceutical outsourcing decision-makers at Rotterdam's World Trade Center this May, putting the spotlight on this critical sector.

The explosive growth of the CDMO sector, marked by a sustained 7% annual growth rate, reflects a fundamental shift in how modern medicines are brought to market. Today, nine out of ten biotechnology companies rely on contract partners to manufacture their breakthrough therapies, making outsourcing a crucial catalyst for pharmaceutical innovation.

"Every day, millions of patients receive life-saving treatments without knowing the crucial role contract manufacturers play," says Luke Bilton, co-founder of CDMO Live. "From COVID-19 vaccines to emerging modalities like GLP-1s driving unprecedented demand for specialised manufacturing capabilities, the CDMO sector has become central to healthcare innovation."

CDMO Live (7-8 May 2025) has rapidly established itself as Europe's essential gathering for the outsourcing ecosystem. The event features

- Talks from senior manufacturing executives from pharmaceutical leaders such as J&J, AstraZeneca, BMS, UCB, Bayer, Valneva, Polpharma and MSD, and revealing new research from Simon Kucher
- Over 50 leading contract manufacturers will showcase cutting-edge capabilities, with the PartnerMatch platform facilitating targeted one-to-one meetings
- Exclusive exclusive networking opportunities, including the CDMO Live Boat Party, Rotterdam city run, a site tour of HALIX's state-of-the-art biologics facility and practical workshops addressing critical industry challenges.

Connecting the outsourcing ecosystem

The event launches at a critical time when pharmaceutical companies face increasing pressure to optimize their external manufacturing networks while maintaining quality and reducing costs.

"Manufacturing strategy has become a board-level priority," says Chris Kilbee, co-founder of CDMO Live. "The complexity of modern medicines, combined with the need for supply chain resilience, has elevated the strategic importance of CDMO partnerships."

"We're bringing together the entire ecosystem - from emerging biotechs to global pharmaceutical leaders - in an environment designed for meaningful connection. With the show floor already sold out, it's clear the industry has been waiting for an event of this calibre."

Supported by key industry associations including PBOA, Pharmaceutical Supply Chain Initiative (PSCI), Rx-360 and Dutch biotech ecosystem partners hollandbio, Leiden Bio Science Park and Rotterdam Square, CDMO Live showcases the Netherlands' emergence as a crucial hub for European pharmaceutical manufacturing, strengthened by the presence of the European Medicines Agency (EMA).

Don't miss out on the opportunity to attend CDMO Live at a discounted rate - early bird tickets are available until 28th February 2025. For more information and registration, visit CDMOLive.com.

Read More